XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 05, 2018
USD ($)
Apr. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Feb. 28, 2018
USD ($)
Mar. 31, 2017
USD ($)
country
Jun. 30, 2019
USD ($)
patent
Patent
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
patent
Patent
Jun. 30, 2018
USD ($)
Commitments And Contingencies [Line Items]                  
Milestone payments     $ 75,000            
License fee           $ 162,500 $ 250,000 $ 275,000 $ 350,000
ADVA Tec Agreement                  
Commitments And Contingencies [Line Items]                  
Number of patents issued | patent           9   9  
Number of pending US patent applications | Patent           1   1  
Number of patents granted | Patent           59   59  
Number of patent applications in other major markets | Patent           4   4  
Licensing Agreements | ADVA Tec Agreement | Ovaprene                  
Commitments And Contingencies [Line Items]                  
Agreement termination period on failing to commercialize in certain designated countries         3 years        
Agreement termination on failing to enroll patient within months of production and release         6 months        
Prior written notice period for termination of agreement for both parties       60 days          
Licensing Agreements | ADVA Tec Agreement | Minimum                  
Commitments And Contingencies [Line Items]                  
Number of designated European countries | country         3        
Percentage of royalty rate         1.00%        
Licensing Agreements | ADVA Tec Agreement | Minimum | Ovaprene                  
Commitments And Contingencies [Line Items]                  
Minimum spending amounts per year         $ 5,000,000        
Licensing Agreements | ADVA Tec Agreement | Maximum                  
Commitments And Contingencies [Line Items]                  
Percentage of royalty rate         10.00%        
Juniper Pharmaceuticals, Inc.                  
Commitments And Contingencies [Line Items]                  
Potential annual license maintenance fee, payments in year one   $ 50,000              
Potential annual license maintenance fee payments, thereafter   $ 100,000              
License agreement, period of continuation from date of first commercial sale of product or process   10 years              
License agreement notice period of termination for breach of payment obligation   30 days              
Period of dismissal of bankruptcy petition   90 days              
License agreement notice period of termination for breach of other obligation   60 days              
License agreement, notice period of termination   180 days              
Juniper Pharmaceuticals, Inc. | Clinical And Regulatory Milestones                  
Commitments And Contingencies [Line Items]                  
Maximum potential milestone payments   $ 13,500,000              
Juniper Pharmaceuticals, Inc. | Sales Milestones                  
Commitments And Contingencies [Line Items]                  
Maximum potential milestone payments   $ 30,300,000              
Juniper Pharmaceuticals                  
Commitments And Contingencies [Line Items]                  
License agreement, termination period prior to receipt of approval   90 days              
Upfront license fee paid   $ 250,000              
SST                  
Commitments And Contingencies [Line Items]                  
License agreement, termination period due to performance failure         60 days        
Percentage of rights to inventions by employees under license agreement       50.00%          
License agreement, expiration period       10 years          
License agreement, termination period prior to receipt of approval       90 days          
License agreement, termination period after receipt of approval       180 days          
License agreement, termination period for applicable license products of applicable countries       30 days          
SST | Minimum                  
Commitments And Contingencies [Line Items]                  
Milestone payments, contingent amount       $ 500,000.0          
Secured investment required for license agreement       10,000,000          
SST | Maximum                  
Commitments And Contingencies [Line Items]                  
Milestone payments, contingent amount       $ 18,000,000          
SST | License And Collaboration Agreement                  
Commitments And Contingencies [Line Items]                  
Percentage of rights to inventions by employees under license agreement       50.00%          
Orbis | Development And Option Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments     $ 300,000            
Commencement period for stage two upon achievement of stage one     90 days            
MilanaPharm | Licensing Agreements                  
Commitments And Contingencies [Line Items]                  
License fee $ 25,000                
License fee to be paid upon contingency 200,000                
Proceeds raised from equity financing 10,000,000                
MilanaPharm | Assignment Agreement                  
Commitments And Contingencies [Line Items]                  
License fee to be paid upon contingency 300,000                
Hammock Pharmaceuticals, Inc. | Assignment Agreement                  
Commitments And Contingencies [Line Items]                  
License fee 250,000                
License fee to be paid upon contingency 250,000                
Proceeds raised from equity financing 10,000,000                
Upon Achieving Certain Commercial Milestones | SST | License And Collaboration Agreement | Maximum                  
Commitments And Contingencies [Line Items]                  
Milestone payments, contingent amount       $ 100,000,000          
Upon Achieving Certain Commercial Milestones | MilanaPharm | Licensing Agreements | Maximum                  
Commitments And Contingencies [Line Items]                  
Milestone payments, contingent amount 1,750,000                
Upon Signing Of Development And Option Agreement | Orbis | Development And Option Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments     $ 150,000            
Upon Completion Of Fifty Percent Development Not Later Than Six Months | Orbis | Development And Option Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments     $ 75,000            
Upon Achieving Certain Clinical And Regulatory Development Milestones | Hammock Pharmaceuticals, Inc. | Assignment Agreement | Maximum                  
Commitments And Contingencies [Line Items]                  
Milestone payments, contingent amount $ 1,100,000                
Upon Achievement Of Specified Development And Regulatory Milestones | Licensing Agreements | ADVA Tec Agreement | Maximum                  
Commitments And Contingencies [Line Items]                  
Milestone payments         $ 14,600,000        
Upon Reaching Certain Worldwide Net Sales Milestones | Licensing Agreements | ADVA Tec Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments         $ 20,000,000        
Future Milestone Payments Based On Product Development [Member] | Licensing Agreements | ADVA Tec Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments               $ 14,600,000  
Future Milestone Payments Based On Commercialization [Member] | Licensing Agreements | ADVA Tec Agreement                  
Commitments And Contingencies [Line Items]                  
Milestone payments               $ 20,000,000